|Last Price$14.85||Day Change (%)-6.25%|
|Open Price$15.12||Day Change ($)-0.99|
|Day Range14.66–15.55||52-Week Range12.56–88.54|
As of Fri 6/24/2016 5:00:00 PM | USD
Robbins Arroyo LLP: Endo International plc ( ENDP ) Misled Shareholders According to a Recently Filed Class Action
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation of Endo International plc and Advises Investors with Losses to Contact the Firm
SHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims Against Endo International plc And Advises Investors With Losses To Contact The Firm
Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Endo International plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
Endo Pharmaceuticals ENDP announced July 11 that it no longer expects to file a new drug application for its ketoprofen pain-relief patch by the first half of 2008 because of lackluster Phase III trial results. The drug candidate failed to show statistically significant results for pain relief in ...
Despite the sector looking slightly overvalued overall, we still see stocks that offer attractive valuations across the different industries.
Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.
As credit spreads have tightened on a nearly continuous trend over the past year, they are becoming richly valued relative to their historical average.
The corporate bond market will probably struggle to return much above break-even in 2014.